StockData
Takeda Pharmaceutical Co Ltd logo

Takeda Pharmaceutical Co Ltd

TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30
$21.77+0.36 (+1.68%)

Close on Nov 20, 2026Market cap $75.03BP/E –Yield –

Takeda Pharmaceutical Adjusted Net Debt to Adjusted EBITDA Leverage Ratio by Quarter

Adjusted Net Debt to Adjusted EBITDA Leverage Ratio (×)

Periods

Takeda Pharmaceutical Adjusted Net Debt to Adjusted EBITDA Leverage Ratio: 2.50× in Q2 FY27, down 7.4% from a year earlier. That is the lowest of the 11 quarters on record here.

Latest, Q2 FY27
2.50
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
-7.4%
2.70 in Q2 FY26
History
11 quarters
Since Q4 FY24
Sources
10
Documents cited below

Where the Q2 FY27 figure comes from

“|| Adjusted Net Debt/Adjusted EBITDA ratio | 2.5x | Proceeds from issuance of bonds | 526.1 | —”

Source: SEC EDGAR Filing (exhibit991_102926.htm) ↗

Reported in Form 6-K Exhibit 99.1 Quarterly Financial Appendix.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdjusted Net Debt to Adjusted EBITDA Leverage Ratio (×)Year on yearSource
Q2 FY27CQ3 2026Sep 30, 20262.50-7.4%SEC EDGAR Filing (exhibit991_102926.htm) ↗
Q1 FY27CQ2 2026Jun 30, 20262.70-6.9%SEC EDGAR Filing (exhibit991_073026.htm) ↗
Q4 FY26CQ1 2026Mar 31, 20262.60-7.1%SEC EDGAR Filing (exhibit991_051326.htm) ↗
Q3 FY26CQ4 2025Dec 31, 20252.700.0%SEC EDGAR Filing (exhibit991_012926.htm) ↗
Q2 FY26CQ3 2025Sep 30, 20252.70-6.9%SEC EDGAR Filing (exhibit991_103025.htm) ↗
Q1 FY26CQ2 2025Jun 30, 20252.90-6.5%SEC EDGAR Filing (exhibit991_073025.htm) ↗
Q4 FY25CQ1 2025Mar 31, 20252.80-9.7%SEC EDGAR Filing (exhibit991_050825.htm) ↗
Q3 FY25CQ4 2024Dec 31, 20242.70–SEC EDGAR Filing (exhibit991_013025.htm) ↗
Q2 FY25CQ3 2024Sep 30, 20242.90–SEC EDGAR Filing (exhibit991_103124.htm) ↗
Q1 FY25CQ2 2024Jun 30, 20243.10–SEC EDGAR Filing (exhibit991_073124.htm) ↗
Q4 FY24CQ1 2024Mar 31, 20243.10–SEC EDGAR Filing (exhibit991_073124.htm) ↗

Breakdown

What makes up adjusted Net Debt to Adjusted EBITDA Leverage Ratio

Cite this data

StockData. (2026). Takeda Pharmaceutical Adjusted Net Debt to Adjusted EBITDA Leverage Ratio (×), quarterly Q4 FY24–Q2 FY27 [Data set]. Compiled from Takeda Pharmaceutical SEC filings and investor materials. https://stockdatahq.com/stocks/tak/kpis/sec-leverage-ratio

See every metric in the Takeda Pharmaceutical KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?